Annexin Pharmaceuticals AB (publ) (STO:ANNX)

Sweden flag Sweden · Delayed Price · Currency is SEK
15.05
+0.10 (0.67%)
Apr 29, 2026, 12:34 PM CET
-46.44%
Market Cap 105.53M
Revenue (ttm) n/a
Net Income (ttm) -39.44M
Shares Out 7.06M
EPS (ttm) n/a
PE Ratio n/a
Forward PE 5.38
Dividend n/a
Ex-Dividend Date n/a
Volume 269
Average Volume 8,978
Open 14.55
Previous Close 14.95
Day's Range 14.55 - 15.05
52-Week Range 11.65 - 41.20
Beta 0.24
RSI 53.70
Earnings Date May 13, 2026

About STO:ANNX

Annexin Pharmaceuticals AB (publ), a clinical stage biotechnology company, develops drug candidates for the treatment of various cardiovascular diseases. It develops ANXV, a human recombinant protein and Annexin A5, natural protein that protects and repairs cells, as well as counteract unwanted inflammatory and immune cell reactions that is in phase 2 clinical phase for the treatment of ophthalmology, oncology, sickle cell disease, and cardiovascular disease. Annexin Pharmaceuticals AB (publ) was incorporated in 2014 and is based in Stockholm, ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 4
Stock Exchange Nasdaq Stockholm
Ticker Symbol ANNX
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.